We have developed a high-level production system for the C-terminal domain of secretory leukoprotease inhibitor (SLPI) to investigate its pharmacological activities. A gene for the C-terminal domain of SLPI, (Asn55-AIalO7)SLPI, was constructed from chemically synthesized deoxyoligonucleotides. It was fused to a gene for the N-terminal portion of human growth hormone via a DNA sequence encoding Leu-Val-Pro-Arg, which can be cleaved by thrombin. The fused gene was expressed in Escherichia coli under the control of a trp promoter, and the fusion protein was obtained as an inclusion body. After sulfonation of the cysteine residues, the sulfonated fusion protein was cleaved at the desired site by thrombin. Sulfonated (Asn55-AlalO7)SLPI was refolded in Tris buffer containing reduced and oxidized glutathione. The resulting (Asn55-AlalO7) SLPI was purified by cation-exchange chromatography and reverse-phase high performance liquid chromatography. The final yield was 50 mg/1 culture. (Asn55-AlalO7)SLPI was as active against elastase as, but had less trypsin inhibitory activity than, native SLPI. This system is suitable for the large-scale production of the C-tenninal domain of SLPI, which is an elastase-specific inhibitor.
Introduction
SLPI is a 107-residue, nonglycosylated serine protease inhibitor which inhibits a wide range of proteases including neutrophil elastase and trypsin (Thompson and OhJsson, 1986) . It has been reported to be distributed widely in submucosal glands (Franken et al., 1989) . In the respiratory tract, SLPI is produced by serous glandular cells in the central airways and by Clara and goblet cells in the peripheral airways (Water et al., 1986) . The exact physiological function of SLPI is unclear, but its major role is thought to be the protection of the airway epithelial surface from attack by neutrophil elastase (Vogelmeier et al., 1991; Piccioni et al, 1992) .
X-ray crystallographic analyses have shown that SLPI comprises two separate domains of similar architecture, and that each domain has four disulfide bonds (GrUtter et al., 1988 ). An investigation into the relationship between the anti-protease activity of SLPI and its domain structure has demonstrated that the elastase inhibitory activity is located in the C-terminal domain (Kramps et al., 1990) . Several groups have reported that recombinant half-length SLPIs containing the C-terminal domain, which were expressed directly in Escherichia coli © Oxford University Press (Meckelein et al., 1990 (Meckelein et al., , 1991 and Saccharomyces cerevisiae (Stetler et al., 1989) , were as active inhibitors of elastase as full-length SLPI. However, the expression levels of half-length SLPIs were =£ 1.0 mg/1 culture and not sufficient for large-scale production. Furthermore, incorrect signal peptide processing in E.coli and S.cerevisiae in their direct expression systems was reported. It would prove interesting to investigate the pharmacological activities of the C-terminal domain of SLPI in vivo, but a high-level expression system for the preparation of enough half-length SLPI to do so has yet to be developed. Therefore, it would be worth while developing an efficient system for the production of the C-terminal domain of SLPI so as to evaluate its potential therapeutic properties.
We succeeded in producing recombinant human growth hormone (hGH; Dcehara et al., 1984) and the hGH-AB portion, residues 1-138, in E.coli (Doi et al., 1986) . We demonstrated the versatility of the hGH-AB gene as a carrier-handle for a fusion protein expression system. A good yield of the hGH-AB fusion protein is usually produced in an insoluble form in E.coli; consequently, it is quite easy to separate the fusion protein from a disrupted cell lysate. The efficient production of ribonuclease Tl (Ikehara et al., 1986) , insulin-like growth factor I (Nishikawa et al., 1987) and human parathyroid hormone (Gardella et al., 1990) as cleavable hGH-AB fusion proteins has been reported previously.
Here, we describe the high-level expression of a thrombincleavable fusion protein containing hGH-AB and the Cterminal domain of SLPI, (Asn55-AlalO7)SLPI, the cleavage of this fusion protein and the purification of (Asn55-Alal07)SLPI after refolding. We also investigate the elastase and trypsin inhibitory activities of (Asn55-AlalO7)SLPI.
Materials and methods

Materials
Restriction enzymes, T4 polynucleotide kinase and T4 DNA ligase were purchased from Takara Shuzo Co. (Kyoto, Japan). Lysozyme, a-thrombin from bovine plasma, bovine pancreatic trypsin and human neutrophil elastase were purchased from Wako Chemical Industries (Osaka, Japan), Mochida Pharmaceutical Co. (Tokyo, Japan), Sigma Chemical Co. (St Louis, MO) and Elastin Products Co. (Owensville, MO), respectively. The synthetic substrates methoxy succinyl-Ala-Ala-Pro-Val-4-nitroanilide (MeO-Suc-Ala-Ala-Pro-Val-pNA) for elastase and benzoyl-4-nitroanilide (Bz-Arg-pNA) for trypsin were obtained from Bachem Feinchemikalien AG (Bubendorf, Switzerland).
Synthesis and construction of the gene for the C-terminal domain of SLPI
The gene for the C-terminal domain of SLPI, (Asn55-AlalO7)SLPI, was assembled by DNA ligation of six overlapping oligonucleotides, which constituted both strands of the DNA (Figure 1 ). These six oligonucleotides were synthesized using an Applied Biosystems 381A DNA synthesizer on a 0.2 umol scale by the cyanoethyl phosphoamidite method, and purified by electrophoresis on 20% (w/v) polyacrylamide gels. The oligonucleotides, except the two 5' end oligomers, were phosphorylated at their 5' termini with ATP (1 mmol) by incubating with T4 polynucleotide kinase (5 U) in 50 mM Tris-HCl (pH 7.5), containing 10 mM MgCl 2 and 5 mM dithiothreitol at 37°C for 2 h. After heat denaturation of the T4 polynucleotide kinase at 100°C for 10 min, the oligonucleotides were combined and annealed by heating to 95°C and gradual cooling to room temperature over the course of 3 h. This mixture was treated with the T4 ligase system of a DNA ligation kit (Takara Shuzo Co.) at 16°C for 12 h. The resultant DNA segment was purified by electrophoresis on a 5% (w/v) polyacrylamide gel. The synthetic gene (6 (i.g) was ligated with the large fragment (3.10 kbp, 1 (ig) obtained from the digestion of pUC119 (Takara Shuzo Co.) with BamHl and Psil. E.coli HB101 was transformed by the ligation mixture, and the recombinant clone harboring the desired plasmid, pUC-D6 (Figure 3 ), was selected by screening. pUC-D6 was prepared using standard procedures (Sambrook et al., 1989) .
Construction of the expression plasmid for the fusion protein
Plasmid pUC-D6 was digested with Mlul and Xhol and the smaller fragment (0.17 kbp) was recovered from 1% (w/v) low melting-temperature agarose gel after electrophoresis. The purified Mlul-Xhol fragment and synthetic BgH\-Mlul linker segment (Figure 2 ), which encodes the thrombin recognition site, were ligated with the larger fragment (4.60 kbp) obtained from plasmid pGH-L9 (Tkehara et al., 1984) by digestion with BgtK and Sail. E.coli HB101 was transformed with the ligation mixture and a transformant carrying an expression plasmid, pGH-TE (Figure 3 ), was obtained.
Expression of the fusion protein
The recombinant E.coli clone harboring the plasmid pGH-TE was grown in modified M9 liquid medium containing casamino acid (20 mg/ml), 0.25% (w/v) glucose and 100 ng/ml ampicillin at 37°C for ~6 h using a 10 1 jar fermenter. When the ODô f the culture medium reached 17.0, 3-indolacrylic acid thrombin cleavage alto (40 (ig/ml) was added to the medium to induce the trp promoter. Incubation was continued for a further 4 h.
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Preparation of sulfonated fusion protein
The cells harvested from a 10 1 culture were collected by centrifugation, suspended in 2 1 0.5 M Tris-HCl (pH 8.0) and treated with lysozyme (1.75 g) at 37°C for 1 h. The cells were disrupted by sonication with a cell disrupter (Ultrasonics, Branson, Danbury, CT) and centrifuged at 17 000 r.p.m.
(3100 g) for 10 min. The pellet containing the fusion protein was washed three times with 0.5 M Tris-HCl (pH 8.0) containing 0.1% (w/v) Triton X-100. The final pellet was dissolved at 45°C in 500 ml 10 M urea, 0.5 M Tris-HCl (pH 8.0), 0.6 M Na 2 SO 3 and 0.1 M Na 2 S 4 O 6 . The supernatant containing the sulfonated fusion protein (8 g) was dialyzed against 10 1 25 mM Tris-HCl (pH 8.0) at 4°C with three changes of buffer for 24 h.
Cleavage of the fusion protein by thrombin
The sulfonated fusion protein (8 g) was treated with bovine plasma a-thrombin (2000 U) in 2 1 50 mM Tris-HCl (pH 8.0) at 37°C for 12 h. Then, 2 ml trifluoroacetic acid were added to stop the enzyme reaction, and the fragments produced were separated by reverse-phase high performance liquid chromatography (HPLC) on a C4 column (Vydac, Hesperia, CA) pre-equilibrated with 0.1% (v/v) trifluoroacetic acid. for the final 10 min. The desired fraction containing the sulfonated (Asn55-AlalO7)SLPI (0.8 g) was eluted by -25% (v/v) acetonitrile, collected and lyophilized.
Refolding and purification of the C-terminal domain of SLPI
The sulfonated (Asn55-Alal07)SLPI (0.8 g) was dissolved in 4 1 50 mM Tris-HCl (pH 8.5) containing 1.5 mM reduced and 0.3 mM oxidized glutathione. This refolding solution was allowed to stand at 4°C for 12 h and then loaded onto an SSepharose (Pharmacia Biosystems, Japan) column equilibrated with 20 mM Tris-HCl (pH 7.5). Elution was carried out with a stepwise gradient of 0.15, 0.30 and 1.00 M NaCl. Folded (Asn55-Alal07)SLPI was eluted by 0.30 M NaCl and purified further by reverse-phase HPLC on a C4 column (Vydac, Hesperia, CA) with an acetonitrile gradient and lyophilized. A total of 500 mg (Asn55-AlalO7)SLPI were obtained from a 10 1 culture. Inhibition assay using synthetic chromogenic substrates 50% inhibitory concentration {IC^). The required inhibitor solution was preincubated at 37°C for 10 min in a total volume of 160 nl mixture comprising 0.1 M HEPES (pH 7.5), 0.5 M NaCl and 20 nM neutrophil elastase. The reaction was started by adding 20 ul MeO-Suc-Ala-Ala-Pro-Val-pNA (final concentration 0.3 mM) and performed at 37°C for 20 min. The light absorbance of the reaction mixture at 405 nm was measured. The residual enzyme activities in the presence of various concentrations of inhibitor were plotted against the concentrations; the IC50 was determined by interpolation.
Inhibition constants (K t values).
The substrates were 0.3 mM MeO-Suc-Ala-Ala-Pro-Val-pNA for elastase and 1.0 mM Bz-Arg-pNA for trypsin. The reaction buffer used for both enzymes comprised 0.1 M HEPES (pH 7.5), 1.0 M NaCl and 0.1% (w/v) PEG-6000. The (Asn55-Alal07)SLPI solution was preincubated at 25°C for 1 h (total volume 160 |il) with 20 nM elastase or 200 nM trypsin. The reactions were started by adding 20 \i\ substrate solution and carried out at 25°C for 20 min. The absorbance of each reaction mixture at 405 nm was recorded and the inhibition constants were determined, as described previously (Henderson, 1972) .
Analytical methods
The DNA sequence of the synthetic gene was verified using an Applied Biosystems 373A DNA sequencer and an Nterminal sequence analysis was performed using an Applied Biosystems Model 470A gas-phase protein sequencer. An amino acid composition analysis was performed on a Waters 712 WISP amino acid analyzer after hydrolysis of the protein with 6 N HC1. A mass spectrum analysis was performed on a Jeol JMS-SX/SX102 tandem mass spectrometer.
Results
Design of the synthetic gene for the C-terminal domain of SLPI
The nucleotide sequence for the synthetic gene encoding the C-terminal domain of SLPI (Figure 1 ) was designed according to the following considerations. The codon usage was optimized by using favorable codons from E.coli (Ikemura, 1981) with respect to the host organism. Two unique restriction sites, Ndel and Bg[Q, were introduced to enable cassette mutagenesis at the reactive site located in the Leu72-Met73-Leu74 sequence of SLPI (Griitter et al., 1988) 1 To ligate the synthetic linker (Figure 2 ) encoding the thrombin-cleavable sequence and to construct the full-length SLPI gene, a Mlul restriction site was introduced.
Construction of the expression plasmid
The vector pGH-L9, described by Ikehara et al. (1984) , was used as the parent vector to construct the expression system for the C-terminal domain of SLPI. It is an efficient expression vector for hGH and contains an inducible trp promoter. The synthetic BglU-Mlul linker (Figure 2 ) encoding the thrombin recognition site and the Mlul-Xhol fragment encoding the Cterminal domain of SLPI in the cloning plasmid pUC-D6 ( Figure 3) were inserted into the BglU and Sail sites of pGH-L9. The expression plasmid, pGH-TE (Figure 3 ), for the fusion protein of the hGH-AB portion and (Asn55-AlalO7)SLPI via the Leu-Val-Pro-Arg sequence was thus obtained and the insert sequences were confirmed by DNA sequencing.
Expression of the C-terminal domain as a thrombincleavable fusion protein
E.coli harboring pGH-TE was grown in modified M9 medium containing ampicillin. After culture for 6 h, gene expression was induced by adding 3-indolacrylic acid. The cells were cultured for a further 4 h, harvested by centrifugation and disrupted by sonication. The SDS-PAGE analysis results of the total, soluble and insoluble proteins in host cells are shown in Figure 4 . The yield of the hGH-AB-(Asn55-Alal07)SLPI fusion protein was -35% of total cellular protein. The desired fusion protein was obtained as an inclusion body, which was sulfonated after solubilization, because the linearized soluble protein is thought to be suitable for subsequent digestion with thrombin.
Cleavage of the sulfonated fusion protein
The time course of proteolytic cleavage of the sulfonated fusion protein by thrombin was analyzed using SDS-PAGE. Restricted fragmentation was observed ( Figure 5) . A 5.5 kDa protein, sulfonated (Asn55-AlalO7)SLPI, was detected among the fragments after incubation at 37°C for 6 h; it was not fusion protein fragmented after incubation for a further 24 h ( Figure 5 ). The reaction mixture was loaded directly onto a C4 column and eluted with an acetonitrile gradient (Figure 6 ), as described in Materials and methods. The 5.5 kDa protein was eluted by -25% (v/v) acetonitrile. Its N-terminal amino acid sequence was Asn-Pro-Thr-Arg-Arg, which corresponds to that of (Asn55-AlalO7)SLPI. These results demonstrate that the fusion protein was cleaved by thrombin at the desired ArgAsn site, and confirm that the amino acid composition of this 5.5 kDa protein is identical to that of (Asn55-AlalO7)SLPI (Table I) . A mixture of fragments cleaved from the hGH-AB portion by thrombin was eluted by -38% (v/v) acetonitrile.
Refolding and purification of the C-terminal domain
As sulfonated (Asn55-AlalO7)SLPI is not biologically active, disulfide bond formation is necessary to obtain an active halflength SLPI. Sulfonated (Asn55-Alal07)SLPI was dissolved in Tris buffer containing oxidized and reduced glutathione. Renaturation was carried out at 4°C for 12 h. The reaction mixture was loaded directly onto a cation-exchange column and chromatographed with a stepwise gradient of NaCl; the elution pattern is shown in Figure 7a (Asn55-Alal07)SLPI (5.5 kDa), a major product, was eluted by 0.3 M NaCl, purified further by reverse-phase HPLC and lyophilized. The reversephase HPLC profile of purified (Asn55-Alal07)SLPI is shown in Figure 7b ; its IC50 for human neutrophil elastase was 1.0 X10" 8 M. Incorrectly refolded monomeric derivatives (5.5 kDa) were eluted as minor products by 0.15 M NaCl. A mixture of oligomers, including a dimer (11.0 kDa) and a trimer (16.5 kDa), was eluted by 1.0 M NaCl. The IC50 values of the monomeric derivatives and oligomers were 5.8X10" 8 and 2.7 X10" 7 M respectively, and their inhibitory activities were lower than that of refolded (Asn55-AlalO7)SLPI. The molecular weight of the resulting (Asn55-AlalO7)SLPI, determined by a mass spectrum analysis, was 5818, which corresponds to that of (Asn55-Alal07)SLPI with four disulfide bonds. Therefore, we concluded that the disulfide bond formation by the sulfonated (Asn55-AlalO7)SLPI molecule was complete. 
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Inhibitory activities of the C-terminal domain
The K, values were determined using the method of Henderson (1972) . The (Asn55-AlalO7)SLPI K, values for human neutrophil elastase and bovine pancreatic trypsin were 1.2X10-'°a nd 1 .OX 10" 6 M, respectively. The (Asn55-AlalO7)SLPI value for elastase was comparable with, but its trypsin inhibitory activity was lower than, that of native SLPI. Smith and Johnson (1985) reported that the native SLPI K, values for elastase and trypsin were 1.87X10" 10 and 8.28X10" 9 M, respectively.
Discussion
SLPI is generally considered to play a defensive role at the respiratory epithelial surface, protecting against attack by neutrophil elastase (Piccioni et al., 1992) . It has been tested The fusion protein was treated with thrombin. The reaction mixture was loaded onto a C4 column and eluted with an acetonitrile gradient. Peak 1, sulfonated (Asn55-Alal07)SLPI; peak 2, sulfonated fusion protein; peak 3, mixture of fragments derived from the hGH-AB portion. The amino acid composition was determined using a Waters 712 WISP amino acid analyzer after hydrolysis with 6 N HC1.
as a potential anti-elastase drug for the treatment of destructive lung diseases (Lucey et al., 1990; Rudolphus et al., 1991) . The C-terminal domain of SLPI is also a promising candidate for the treatment of conditions in which elastase is involved because it is as active an inhibitor of elastase as full-length SLPI (Stetler et al., 1989; Meckelein et al., 1990) . It would be interesting to investigate the properties of the C-terminal domain of SLPI as a potential therapeutic agent, but little is known about its pharmacological activities in vivo. Several groups have succeeded in producing the recombinant C-terminal domain of SLPI. Meckelein et al. (1990) reported that the C-terminal domain of SLPI could be expressed directly in E.coli using the signal sequence of alkaline phosphatase with overall yields of 0.5-1.0 mg/1 bacterial culture, but the signal peptide processing in their system was incorrect. Stetler et al. (1989) reported that the active C-terminal domain of SLPI was secreted by S.cerevisiae, but the yield was no more than 1.0 mg/1 culture. In these secretory expression systems, the yields are too low to enable sufficient C-terminal domain of SLPI to be prepared for an in vivo bioassay. SLPI has been reported to bind to mRNA and DNA in E.coli via charge interactions and to cause cellular toxicity (Miller et al., 1989) . These authors suggested that, in general, the high-level expression of basic proteins in E.coli may be problematic. Therefore, we speculate that the high-level direct expression of SLPI and its derivatives may be difficult because SLPI has a strong positive charge.
Here we have demonstrated the high-level expression of the cleavable fusion protein containing hGH-AB as the N-terminal region and (Asn55-Alal07)SLPI as the C-terminal region, correct cleavage at the desired site by thrombin, the formation of disulfide bonds and the purification of active (Asn55-AlalO7)SLPI by a simple two-step chromatographic method. The fusion protein obtained as an inclusion body had low solubility because it was aggregated by random disulfide bond formation and the hydrophobic character of hGH-AB portion. of the hGH-AB-(Asn55-AlalO7)SLPI fusion protein is not sufficient for solubilization. One useful way of solubilizing denatured proteins would be to increase their net charge, and S-alkylation of cystein residues has been reported to increase the solubility of cystein-containing denatured proteins (Yamada et al., 1994) . To solubilize and linearize denatured hGH-AB-(Asn55-AlalO7)SLPI, nine cystein residues in the fusion protein were sulfonated. Indeed, the sulfonated hGH-AB-(Asn55-AlalO7)SLPI having a negative net charge was soluble and completely cleaved by thrombin at the desired site. Another advantage is that the sulfonation of (Asn55-AlalO7)SLPI is reversible, so that refolded (Asn55-AlalO7)SLPI is obtained in aqueous solution. We suggest that sulfonation would be very useful at solubilizing cystein-rich denatured proteins. The expression plasmid pGH-TE for the fusion protein retains several useful features of the starting plasmid pGH-L9 (Dcehara et al., 1984) . It possesses the strong E.coli trp promoter, the optimized space between the ribosome-binding site and the initiation codon of the hGH gene, and codons found most frequently in E.coli genes. We speculate that the high-level production of the C-terminal domain of SLPI was achieved in our study because its capacity for binding mRNA and DNA in E.coli may be reduced compared with native SLPI by the hGH-AB portion. Our system produced up to 50 mg purified (Asn55-Alal07)SLPI/l culture, a considerably better yield than obtained by direct expression in E.coli and S.cerevisiae.
The (Asn55-Alal07)SLPI K, value for elastase was comparable with that of native SLPI as reported by Smith and Johnson (1985) , but its trypsin inhibitory activity was lower. Stetler et al. (1989) reported that (Leu48-AlalO7)SLPI expressed by S.cerevisiae had no inhibitory activity against trypsin, whereas Meckelein et al. (1990) reported that (Asp49-AlalO7)SLPI secreted by E.coli had a weak anti-trypsin activity. Our results agree with the inhibitory activities of the C-terminal domain of SLPI reported previously by Meckelein et al. (1990) . We suggest that the active inhibitory sites against elastase and trypsin are located in the C-terminal domain, and that the Nterminal domain plays a cooperative role in inhibiting trypsin. The C-terminal domain may be a pharmacologically useful SLPI derivative because it shows greater specificity for elastase than trypsin and is smaller than full-length SLPI. The smaller size of this protein may allow for a proportionately smaller therapeutic dose of (Asn55-AlalO7)SLPI than full-length SLPI.
The fusion protein expression system we have described provides an efficient and consistent means of producing the highly purified C-terminal domain of SLPI. Adequate amounts of (Asn55-AlalO7)SLPI for in vivo evaluation can be obtained using our strategy, and we are currently investigating its pharmacological activities and pharmacokinetic properties.
